General characteristics and therapeutic options in lung cancer in Turkey
dc.authorid | 0000-0001-8650-299X | en_US |
dc.authorid | 0000-0003-1645-7761 | en_US |
dc.authorid | 0000-0001-6618-6774 | en_US |
dc.authorid | 0000-0001-8125-9062 | en_US |
dc.authorid | 0000-0003-1645-7761 | en_US |
dc.authorid | 0000-0002-8488-3650 | en_US |
dc.contributor.author | Özlü, Tevfik | |
dc.contributor.author | Bülbül, Yılmaz | |
dc.contributor.author | Arınç, Sibel | |
dc.contributor.author | Özyürek, Berna A. | |
dc.contributor.author | Günbatar, Hulya | |
dc.contributor.author | Yaşar, Zehra Aşuk | |
dc.contributor.author | Talay, Fahrettin | |
dc.date.accessioned | 2021-06-23T19:41:56Z | |
dc.date.available | 2021-06-23T19:41:56Z | |
dc.date.issued | 2015 | |
dc.department | BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.description.abstract | ASPECT study, a prospective multicenter study conducted in Turkey with the participation of 26 centers, including all patients with lung cancer, who agreed to participate in the study, were re-evaluated in terms of demographic characteristics of patients (pts), disease characteristics, and the treatment options in lung cancer. Among 1245 cases (88.7% man) included, %83.4 had advanced stage (stage 3-4) lung cancer. Histopathologic types were squamous cell in 39.3%, adenocancer in 29.6%, SCLC in 19.0%, NSCLC in 10.2% and others. Of the pts, 45.5% had a comorbid disease, 49.3% had weight loss (at least 5% of body weight), and 31.6% had a history of cancer in family. PET-CT was used in 83.3% of the pts for diagnosis of staging. Metastasis was detected in 54.2% of pts (43.9% bone, 23.1% brain, %20.2% liver, 17.3% surrenal metastasis). Treatment options were chemotherapy in 45.9%, chemo-radiotherapy in 28.2%, and surgery in 18.4% of the pts. Chemotherapy was mostly platin based doubles including etoposide (14.9%), paclitaxel (14.0%), gemcitabine (12.3%), docetaxol (4.3%), pemetrexed (2.2%), vinorelbin (4.9%), and others. The use of targeted therapies was detected in 1.1% of the pts. Palliative radiotherapy was given in 21.1% of the pts (8.5% brain, 7.2% bone, 6.7% thorax, and others). Interventional bronchoscopy or bronchial stenting was performed in 2.0% and pleurodesis in 1.8%. Of the pts, 10.5% reported the use of herbal medicine products. Most pts with lung cancer presented in advanced stages and only 18.4% had a chance for surgery. Conventional chemotherapy and radiotherapy was the most common therapeutic options but the use of targeted therapies and interventional procedures seems to be quite low. | en_US |
dc.identifier.doi | 10.1183/13993003.congress-2015.PA4311 | |
dc.identifier.issn | 0903-1936 | |
dc.identifier.issn | 1399-3003 | |
dc.identifier.uri | https://doi.org/10.1183/13993003.congress-2015.PA4311 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12491/8235 | |
dc.identifier.volume | 46 | en_US |
dc.identifier.wos | WOS:000451979406201 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.institutionauthor | Yaşar, Zehra Aşuk | |
dc.institutionauthor | Talay, Fahrettin | |
dc.language.iso | en | en_US |
dc.publisher | European Respiratory Soc Journals Ltd | en_US |
dc.relation.ispartof | European Respiratory Journal | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Lung cancer / Oncology | en_US |
dc.subject | Neoplastic Diseases | en_US |
dc.subject | Mediastinal Tumour | en_US |
dc.title | General characteristics and therapeutic options in lung cancer in Turkey | en_US |
dc.type | Conference Object | en_US |